Breadcrumb

[A20-15] Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2020-02-17 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 31 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G16-02] Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed

[A20-14] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-66] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-40] Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2020-05-15 Extract of dossier assessment (German version) 31 kBPDFdownload file
2020-05-15 Dossier assessment (German version) 373 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close